Nutrition and Clinical Services Division, International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh.
The University of Queensland, Brisbane, QLD, Australia.
PLoS One. 2023 Jan 27;18(1):e0280934. doi: 10.1371/journal.pone.0280934. eCollection 2023.
Fibersol-2 has innumerable beneficial effects on human health. It is a fermentable, non-viscous, water-soluble, indigestible dextrin containing 90% dietary fiber produced from corn starch. We aimed to evaluate whether additional intake of Fibersol-2 along with oral rehydration solution treatment can reduce the duration of watery diarrhea and daily stool output in children 1-3 years as well as recovery of such children within 72 hours, compared to placebo.
This placebo-controlled double-blinded, randomized parallel two arm trial conducted in Kumudini Women's Medical College Hospital in rural Bangladesh between March and October, 2018 used 5 gm of either Fibersol-2 or placebo dissolved in 50-ml drinking water which was given orally to ninety-two children with watery diarrhea on enrollment twice daily for a period of 7 days. Randomization was done using a randomization table. We randomly allocated 45 (49%) and 47 (51%) children in Fibersol-2 and placebo groups, respectively. Outcome measures were duration of resolution of watery diarrhea, daily stool output and the proportion of children recovered within 72 hours. Primary and safety analyses were by intention to treat. This trial was registered at ClinicalTrials.gov, number NCT03565393.
There was no significant difference observed in terms of duration of resolution of diarrhea (adjusted mean difference 8.20, 95% CI -2.74 to 19.15, p = 0.14, adjusted effect size 0.03); the daily stool output (adjusted mean difference 73.57, 95% CI -94.17 to 241.32, p = 0.38, adjusted effect size 0.33) and the proportion of children recovered within 72 hours (adjusted odds ratio 0.49, 95% CI = 0.12 to 1.96, p = 0.31, adjusted risk difference -0.06 (95% CI -0.19 to -0.06), after regression analysis between Fibersol-2 and placebo.
No beneficial role of Fibersol-2 was observed in diarrheal children aged 1-3 years.
This trial is registered at ClinicalTrials.gov, number NCT03565393. The authors confirmed that all ongoing and related trials for this drug/intervention are registered. https://clinicaltrials.gov/ct2/show/NCT03565393.
Fibersol-2 对人类健康有无数益处。它是一种可发酵的、非粘性的、水溶性的、不可消化的糊精,由玉米淀粉制成,含有 90%的膳食纤维。我们旨在评估在口服补液溶液治疗的基础上,额外摄入 Fibersol-2 是否可以缩短 1-3 岁儿童水样腹泻的持续时间和每日粪便量,并在 72 小时内恢复此类儿童,与安慰剂相比。
这项在孟加拉国农村 Kumudini 妇女医学院医院进行的安慰剂对照、双盲、随机平行双臂试验于 2018 年 3 月至 10 月进行,使用 5 克 Fibersol-2 或安慰剂溶解在 50-ml 饮用水中,在招募时每日两次口服给 92 名患有水样腹泻的儿童,持续 7 天。使用随机数表进行随机分组。我们分别将 45 名(49%)和 47 名(51%)儿童随机分配到 Fibersol-2 和安慰剂组。主要和安全性分析均为意向治疗。该试验在 ClinicalTrials.gov 注册,编号为 NCT03565393。
在腹泻缓解的持续时间方面,未观察到显著差异(调整后的平均差异 8.20,95%CI-2.74 至 19.15,p=0.14,调整后的效应大小 0.03);每日粪便量(调整后的平均差异 73.57,95%CI-94.17 至 241.32,p=0.38,调整后的效应大小 0.33)和 72 小时内恢复的儿童比例(调整后的优势比 0.49,95%CI=0.12 至 1.96,p=0.31,调整后的风险差异-0.06(95%CI-0.19 至-0.06)),在 Fibersol-2 和安慰剂之间进行回归分析后。
在 1-3 岁腹泻儿童中,Fibersol-2 没有观察到有益作用。
本试验在 ClinicalTrials.gov 注册,编号为 NCT03565393。作者确认该药物/干预的所有正在进行和相关试验均已注册。https://clinicaltrials.gov/ct2/show/NCT03565393。